Kura Oncology Inc is a clinical-stage biopharmaceutical company, that engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small-molecule product candidates that target cell signalling pathways to drive the progressi... Kura Oncology Inc is a clinical-stage biopharmaceutical company, that engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small-molecule product candidates that target cell signalling pathways to drive the progression of various cancers. The company has a lead product candidate, Tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. It is advancing KO-947, a small molecule inhibitor of extracellular-signal-regulated kinase (ERK), as a treatment for patients with pancreatic cancer, colorectal cancer, non-small cell lung cancer (NSCLC) and melanoma. Geographically operation of the group is carried through the United States. Show more
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.19 | 3.41113105925 | 5.57 | 6.14 | 5.48 | 2885845 | 5.88091542 | CS |
4 | -1.57 | -21.4188267394 | 7.33 | 8.04 | 5.41 | 1499926 | 6.34954631 | CS |
12 | -1.58 | -21.5258855586 | 7.34 | 9.16 | 5.41 | 1567489 | 7.49468424 | CS |
26 | -12.58 | -68.5932388222 | 18.34 | 19.7283 | 5.41 | 1708096 | 9.47622662 | CS |
52 | -13.05 | -69.3779904306 | 18.81 | 23.48 | 5.41 | 1168405 | 12.40846478 | CS |
156 | -10.13 | -63.7507866583 | 15.89 | 24.17 | 5.41 | 987763 | 13.51605597 | CS |
260 | -4.23 | -42.3423423423 | 9.99 | 42.82 | 5.41 | 875060 | 16.43861087 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions